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It has been proposed that the E2F1 transcription factor serves as a link between the Rb/E2F proliferation
pathway and the p53 apoptosis pathway by inducing the expression of p19ARF, a protein that regulates p53
stability. We find that although p19ARF contributes to p53 accumulation in response to E2F expression,
p19ARF is not required for E2F1-mediated apoptosis. E2F1 can signal p53 phosphorylation in the absence of
p19ARF, similar to the observed modifications to p53 in response to DNA damage. These modifications are not
observed in the absence of p19ARF following expression of E2F2, an E2F family member that does not induce
apoptosis in mouse embryo fibroblasts but can induce p19ARF and p53 protein expression. p53 modification
is found to be crucial for E2F1-mediated apoptosis, and this apoptosis is compromised when E2F1 is coex-
pressed with a p53 mutant lacking many N- and C-terminal phosphorylation sites. Additionally, E2F1-
mediated apoptosis is abolished in the presence of caffeine, an inhibitor of phosphatidylinositol 3-kinase-
related kinases that phosphorylate p53. These findings suggest that p53 phosphorylation is a key step in
E2F1-mediated apoptosis and that this modification can occur in the absence of p19ARF.
The p53 tumor suppressor is an important sensor that re-
sponds to various cellular stresses including DNA damage and
inappropriate proliferation. DNA damaging agents and gam-
ma-irradiation cause phosphorylation and subsequent accumu-
lation and activation of p53 (23). As a result, a cell will either
arrest and allow for DNA repair or commit programmed cell
death (73, 78). Additionally, expression of cellular or viral
oncoproteins that promote proliferation, such as c-myc or ad-
enovirus E1A, results in p53-dependent apoptosis (13, 27). A
role for the E2F family member E2F1 has been well estab-
lished in activating the p53 apoptotic signaling pathway upon
loss of proliferation control, and recent reports suggest that
E2F1 may contribute to apoptosis in response to DNA damage
(6, 30, 43).
During normal cell proliferation, E2F family members mod-
ulate the expression of many genes involved in the transition
from G1 to S phase and DNA replication (53). E2F transcrip-
tional activity is regulated by interaction with members of the
retinoblastoma (Rb) family of proteins (24). Inactivation of Rb
by cellular or viral oncoproteins or loss of Rb will stimulate
cells to bypass G0/G1 and enter S phase (17, 19, 50, 52). S-
phase induction also occurs when E2F1, E2F2, or E2F3 is
exogenously expressed in quiescent cells (15, 35, 40). There is
evidence that ectopic expression of various E2F family mem-
bers can induce both S-phase progression and apoptosis, de-
pending on the levels of expressed cDNA or cell type context
(12, 28, 40, 59, 72, 74, 79). However, in fibroblasts, exogenous
expression of E2F1, but not E2F2 or E2F3, causes apoptosis
(15, 39).
The link between E2F1 and p53-dependent apoptosis has
been demonstrated by genetic studies in mice. Apoptosis ob-
served in transgenic mouse models expressing a fragment of
the simian virus 40 large-T antigen and in the central nervous
system of Rb/ mouse embryos is p53-dependent and associ-
ated with E2F1 (46, 56, 69). Additionally, expression of an
E2F1 transgene in the skin of K5E2F1 transgenic mice results
in increased proliferation and p53-dependent apoptosis (57).
Recent reports have also identified a p53-independent mech-
anism of E2F1-induced apoptosis that is mediated by the p53
homologue p73 (44, 67). E2F1 is able to directly transactivate
the p73 promoter, thereby inducing a cell cycle arrest and
apoptosis (33, 67).
E2F1 has been shown to transactivate the expression of the
mouse p19ARF and human p14ARF promoters (4, 32, 60).
p19ARF encodes a protein that modulates the activity of
Mdm2 (58, 77). Mdm2 is an E3-like ubiquitin ligase that reg-
ulates the stability of p53 by promoting its degradation by the
proteasome (21, 22, 26, 31). By inhibiting Mdm2 activity,
p19ARF allows stabilization, activation, and accumulation of
p53 protein (58, 77). Thus, it has been hypothesized that
p19ARF is a key protein linking the Rb/E2F and p53 pathways
(4, 37). One hypothesis for how aberrations in the Rb/E2F
pathway are recognized by p53 is that deregulated E2F expres-
sion activates p53 by inducing p19ARF.
Although the three E2F proteins that induce S phase (E2F1,
E2F2, and to a lesser extent, E2F3) also induce p19ARF ex-
pression (15), only E2F1 induces p53-dependent apoptosis in
fibroblasts. These observations suggest that there may be dif-
ferent pathways for E2F1 to signal p53-mediated apoptosis and
p53 accumulation. We demonstrate that although p19ARF
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contributes to p53 accumulation, it is not required for E2F1-
mediated apoptosis. We also find that E2F1 expression results
in the phosphorylation of N-terminal serine residues on p53,
similar to the p53 modifications observed in response to DNA
damage. Covalent modification of p53 is required for E2F1-
mediated apoptosis and occurs independent of p19ARF status.
Moreover, E2F2 expression, which does not induce apoptosis
in mouse embryo fibroblasts (MEFs), does not lead to the
phosphorylation of serine residues on p53 in the absence of
p19ARF.
MATERIALS AND METHODS
Cell culture. Early passage wild-type and genetically matched p53/ and
Mdm2//p53/ MEFs were isolated from mouse embryos as described previ-
ously (36). MEFs derived from p19ARF/ mouse embryos were a generous gift
from Charles Sherr (St. Jude Children’s Research Hospital, Memphis, Tenn.).
MEFs derived from p19ARF//p53/ mouse embryos were a generous gift
from Gerard Zambetti (University of Tennessee, Memphis). ink4a/ MEFs
were kindly provided by Ronald DePinho (Harvard Medical School, Boston,
Mass.). MEFs were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.
Adenovirus vectors. Recombinant adenoviruses encoding p53, E2F1, and
E2F2 have been described previously (15, 40, 63). An adenovirus encoding an
E2F1 DNA binding mutant, E2F1e132 (35), was created by homologous recom-
bination (40, 54). The p53N/C virus was generated from the pCB6 plus p53N/C
construct generously provided by Karen Vousden (National Cancer Institute,
Frederick, Md.). Control viruses encode either an empty expression cassette or
-galactosidase. Infection with control virus had no effect on the parameters
tested relative to mock infection (data not shown). Viruses were propagated in
293 cells and purified by centrifugation through cesium-chloride gradients. Virus
titers were determined by immunohistochemical staining for the adenovirus
hexon protein with an anti-adenovirus antibody (Biodesign International) and
visualized by using a 3,3-diaminobenzidine substrate kit from Vector Labora-
tories (10).
Virus infection. Cells were washed once with phosphate-buffered saline (PBS),
and serum-free DMEM containing the virus was added to the cells. Infections
were carried out at 37°C in 5% carbon dioxide (CO2) for 1 h (40). The virus
inoculum was then removed and replaced with DMEM containing the appro-
priate concentration of serum, and the mixture was cultured under the conditions
described above.
Immunoblot analysis. MEFs were infected with AdCon, AdE2F1, AdE2F1e132,
or AdE2F2 at a multiplicity of infection (MOI) of 100, except for lanes marked
E2F1low, which were infected at an MOI of 25. Adp53 was infected at an MOI
of 10 unless stated otherwise. Whole-cell extracts from MEFs were harvested at
24 h postinfection (hpi). Cells were washed twice with cold PBS and lysed in
whole-cell extract buffer (50 mM HEPES [pH 7.9], 250 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 0.1% Nonidet P-40, 1 mM dithiothreitol, 1 mammalian pro-
tease inhibitor cocktail [Sigma], 1 phosphatase inhibitor cocktails I and II
[Sigma]) by incubation for 30 min on ice. Soluble proteins were separated by
centrifugation at 13,000  g in a microcentrifuge, and supernatants were stored
at 70°C. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis analysis and transferred to a polyvinylidene difluoride membrane
(Millipore) by electroblotting. p19ARF was detected with anti-p19ARF poly-
clonal antisera (Novus), p53 protein was detected with monoclonal antibody
D0-1 or polyclonal antiserum Ab-7 (Oncogene Research Products), phospho-
Ser15 and -Ser20 forms of p53 were detected with polyclonal antisera specific for
each modification (Cell Signaling Technologies). Transduced p53N/C and wild-
type p53 were detected with the monoclonal antibody PAb1801 to compare
expression levels (Oncogene Research Products) (see Fig. 7A). Actin was de-
tected with polyclonal antisera I-19 (Santa Cruz Biotechnology, Inc.). Immuno-
reactive proteins were detected by using a chemiluminescence kit (Amersham)
according to the manufacturer’s recommendations. Relative changes in the levels
of p53 were estimated from scanned images of Western blots with Multianalyst
software (Bio-Rad).
Apoptosis analysis by flow cytometry. At the indicated times postinfection,
cells were trypsinized, combined with any floating cells, pelleted, washed with
PBS, repelleted, and resuspended in 400 l of PBS. All centrifugations were at
500  g for 5 min at 4°C. Subsequently, cells were fixed in cold ethanol (final
concentration, 70%) and stored at 4°C. Cells were processed for propidium
iodide (PI) staining as described previously (40). Flow cytometric analysis was
performed by the University of Massachusetts Medical School Flow Cytometry
Core Facility. Cells undergoing apoptosis were defined as the population that
contained less than a 2N DNA content.
Apoptosis analysis by ELISA. Cells were plated in 24-well plates at a concen-
tration of 1  104 cells per well. Virus infections were performed, as described
above, 24 h after plating, and caffeine was added at the indicated doses following
infection. At 72 hpi, cells were centrifuged at 500  g for 10 min at 4°C, and
lysed, and an enzyme-linked immunosorbent assay (ELISA) was performed as
described by the manufacturer (Roche).
Immunohistochemical staining for p53 protein accumulation. Cells were in-
fected with the appropriate adenovirus constructs and immunohistochemically
stained for p53 protein as described previously (39). AdCon, AdE2F1,
AdE2F1e132 were infected at an MOI of 100. At the time of harvest (48 hpi), cells
were washed three times with PBS and then fixed for 15 min each in 3.7%
formaldehyde followed by methanol. The cells were then washed in PBS–0.5%
Tween 20. Cells were then incubated with anti-p53 monoclonal antibody PAb421
(Oncogene Research Products) in the presence of 1% bovine serum albumin in
PBS–0.5% Tween 20 for 45 min at room temperature. The cells were washed
three times with PBS–0.5% Tween 20, and the bound antibody was detected with
a Vectastain 3,3-diaminobenzidine substrate kit as described by the manufac-
turer.
p53 immunofluorescence. Cells were infected with AdCon, AdE2F1, or
AdE2F2 at an MOI of 100, and at 24 hpi, the cells were fixed in 3.7% formal-
dehyde followed by methanol. Fixed cells were incubated with anti-p53 mono-
clonal antibody pAb421 (Oncogene Research Products) and polyclonal antisera
specific for phospho-Ser15 p53 (Cell Signaling Technologies). The bound anti-
bodies were detected with fluorescein isothiocyanate (FITC)- or Rhodamine
Red-X-conjugated secondary antibodies (Jackson Immunoresearch Laborato-
ries, Inc., and Southern Biotechnology Associates, Inc.).
RESULTS
p19ARF is not required for E2F1-mediated apoptosis. Hu-
man p14ARF and mouse p19ARF promoters contain multiple
E2F binding sites that are responsive to ectopic expression of
E2F1 (4, 32, 60). Because p19ARF mRNA levels increase upon
E2F1 expression (15), we wanted to determine whether the
elevated mRNA levels corresponded to an increase in p19ARF
protein levels. Indeed, we found that infecting MEFs with an
adenovirus encoding E2F1 (AdE2F1) led to increased levels of
p19ARF protein (Fig. 1A). Given that p19ARF expression
leads to p53 accumulation via inactivation of Mdm2 functions
and that E2F1 expression leads to p53-dependent apoptosis,
we determined whether p19ARF was required for E2F1-me-
diated p53-dependent apoptosis. We find that E2F1 expression
induced apoptosis regardless of p19ARF status as measured by
the percentage of cells with sub-2N DNA content (Fig. 1B).
Apoptosis is observed at all MOIs in the wild-type MEFs but
only at the highest dose of E2F1 in the p19ARF/ MEFs,
suggesting that while p19ARF is not required, it may contrib-
ute to E2F1-mediated apoptosis. MEFs infected with an ade-
novirus encoding an E2F1 DNA binding mutant, E2F1e132,
showed little or no increase in apoptosis compared to the
controls. The percentage of apoptotic cells was also measured
in p19ARF/ and p19ARF//p53/ MEFs to test the re-
quirement for p53 in the apoptosis observed in p19ARF/
MEFs. The p19ARF//p53/ MEFs were less susceptible to
apoptosis than MEFs lacking only p19ARF (Fig. 1C). In addi-
tion, expression of E2F1 also induced apoptosis in ink4a/
MEFs (unpublished observations). ink4a/ mice do not ex-
press p19ARF because of the deletion of a shared exon with
p16INK4A, which encodes a cyclin-dependent kinase inhibitor
(65). Thus, E2F1 can induce apoptosis in p19ARF-deficient
MEFs that are generated from independent genetic lesions in
mice.
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p19ARF and Mdm2 contribute to p53 accumulation. Given
that apoptosis does not require p19ARF, we asked whether
p19ARF is necessary for E2F1-mediated changes in p53 pro-
tein levels. To address this question, we expressed E2F1 in
p19ARF/ MEFs and assessed p53 protein levels by immu-
nohistochemistry. As shown in Fig. 2A, E2F1 expression re-
sulted in increased levels of endogenous p53 protein in wild-
type MEFs. When E2F1 was expressed in p19ARF/ MEFs,
fewer cells stained positive for p53 protein and more modest
changes in p53 protein levels were observed. The changes in
endogenous p53 protein levels observed by immunohistochem-
ical staining following E2F1 expression correlate with the
changes observed by immunoblotting for endogenous p53 (see
Fig. 5C). Likewise, Nip et al. observed an increase in the
half-life of p53 following E2F1 expression in 32D.3 cells, a
tumor cell line that lacks p14ARF expression (55). In both
MEF genotypes, expressing the E2F1e132 DNA binding mutant
had little or no effect on p53 protein levels. These results are
consistent with a model in which p19ARF can contribute to
E2F1-mediated changes in p53 protein levels.
FIG. 1. E2F1 induces apoptosis in the absence of p19ARF. (A) Immunoblot analysis of p19ARF levels in lysates of wild-type (wt) and
p19ARF/ MEFs. Cells were infected with recombinant adenoviruses encoding E2F1, E2F1e132, or a control (Con) virus. Samples were harvested,
and lysates were generated at 24 hpi. The actin blot is shown as a protein loading control. ns, nonspecific band. (B) Analysis of apoptosis in MEFs.
Wild-type and p19ARF/ MEFs were infected at a MOI of 100, 300, or 500 with virus encoding the marked cDNA. Cells were harvested and fixed
at 72 hpi, stained with PI, and analyzed by flow cytometry. Apoptotic cells were scored as the percentage of cells with a sub-2N DNA content
(marked by the bar in each plot). (C) Analysis of apoptosis in p19ARF/ and p19ARF//p53/ MEFs. Infection and harvest conditions were
the same as described for panel B. Percentages represent cells with sub-2N DNA content.
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p19ARF affects p53 protein levels by binding to Mdm2 and
preventing it from promoting the degradation of p53 (58, 77).
Therefore, we determined whether Mdm2 is necessary for
E2F1-mediated accumulation of p53. It is not possible to du-
plicate the experiments described above for Mdm2 because
there are no cell lines or MEFs available that lack Mdm2
expression but retain endogenous wild-type p53. However,
MEFs can be derived from Mdm2//p53/ embryos (36, 49).
To analyze the effects of E2F1 on p53 protein levels in these
cells, we introduced p53 in trans by infecting cells with an
Adp53 recombinant adenovirus, essentially creating a pseudo
Mdm2/ MEF. To control for the addition of exogenous p53
transcript, wild-type, p19ARF/, and p53/ MEFs were also
infected with Adp53 at the same low MOI. As observed in the
immunohistochemical and immunoblot analysis for endoge-
nous p53, E2F1 expression resulted in a substantial (6-fold)
increase in exogenous p53 levels in wild-type MEFs in com-
parison to control infected cells when measured by immuno-
blot analysis (Fig. 2B) (see Fig. 5C). Others have made similar
observations for p19ARF/ MEFs following retroviral gene
transfer of E2F1 (80). p53 also accumulated in response to
E2F1 in p53/ MEFs that ectopically expressed p53 (Fig. 2B).
Therefore, exogenously expressed p53 protein is affected by
E2F1 in a manner similar to that of the endogenous protein.
Infection with AdE2F1 resulted in a modest (2.4-fold) in-
crease in total p53 protein levels in Adp53-infected p19ARF/
MEFs compared to AdCon infection of the same cell type (Fig.
2B). The basal levels of ectopically expressed p53 were higher
in p19ARF/ MEFs than in wild-type cells. This observation
is consistent with the data obtained by immunostaining and
immunoblotting for endogenous p53 in p19ARF/ MEFs
(Fig. 2A) (see Fig. 5C), although the difference is exaggerated
when cells are infected with Adp53 (Fig. 2B). Others have also
reported higher basal levels of p53 in p19ARF/ MEFs (16).
E2F1 expression minimally affected p53 protein levels in
Adp53-infected Mdm2//p53/ MEFs. We suspect that the
Mdm2 deficiency elevates baseline levels of p53 in these cells
due to an absence or greatly reduced level of p53 ubiquitin
ligase activity. E2F1e132 had little or no effect on p53 protein
levels in each cell type, consistent with a transcriptional mech-
anism being at least partly responsible for E2F1-mediated ac-
cumulation of p53. The reduced ability of E2F1 to alter p53
levels above those of the controls in p19ARF/ MEFs, or in
MEFs lacking Mdm2 but expressing p53, is consistent with a
model in which E2F1 modulates p53 protein levels, in large
part, through the p19ARF/Mdm2/p53 pathway.
E2F expression leads to the phosphorylation of p53. In re-
sponse to DNA damage, p53 is activated by covalent modifi-
cations, including the phosphorylation at certain serines and
acetylation of lysine residues. Of these modifications, phos-
phorylation of Ser15 on human p53, or Ser18 on mouse p53, is
commonly observed in response to DNA damage (3, 7). Given
that both DNA damage (37) and E2F1 do not necessarily
require p19ARF to activate p53, we determined whether
FIG. 2. Contribution of p19ARF and Mdm2 to E2F1-mediated accumulation of p53. (A) Immunohistochemical staining for endogenous p53
protein in wild-type (WT) and p19ARF/ MEFs. Cells were fixed for staining at 48 hpi. (B) Immunoblot analysis for p53 in lysates of wild-type,
p19ARF/, p53/, and Mdm2//p53/ MEFs. Cells were coinfected with Adp53 and AdCon, AdE2F1, or AdE2F1e132. Samples were harvested
at 24 hpi. Actin blots are shown as protein loading controls.
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E2F1-mediated activation of p53 function is coincident with
p53 phosphorylation. To detect phospho-Ser18, we used an
antibody specific for this modification. We find that E2F1 ex-
pression, and to a lesser extent, that of E2F2, in wild-type
MEFs results in an increase in endogenous p53 protein levels
and the phospho-Ser18 form of p53 as detected by immunoflu-
orescence (Fig. 3). When merged, it is apparent that only a
subset of the cells with an increase in total p53 has increased
levels of the phospho-Ser18 form of p53. Total p53 protein and
the phospho-Ser18 form of p53 were present at low levels in
cells infected with the control virus (Fig. 3). These data suggest
that E2F1 may signal p53 accumulation and p53 phosphoryla-
tion by separate pathways.
Differential abilities of E2F1 and E2F2 to phosphorylate p53
and induce apoptosis. To discriminate between E2F1-specific
induction of p53 and increased E2F activity in general, we
measured the levels of p53 in extracts of cells infected with an
adenovirus encoding E2F2 in comparison to E2F1. E2F2 is
functionally similar to E2F1. E2F2 is a potent inducer of S
phase when expressed in quiescent cells, is normally induced at
the G1 to S transition, specifically interacts with Rb, and in-
duces a similar array of genes when overexpressed (15, 34, 42,
51, 64). However, like other E2F family members, E2F2 is
unable to induce apoptosis in REF52 cells (15, 39). We find
that E2F2 expression does not lead to apoptosis in MEFs, even
though it is capable of inducing the expression of p19ARF
protein (see Fig. 5A and B). Ectopic E2F2 expression did
result in increased levels of endogenous p53 protein in wild-
type MEFs, although not as effectively as E2F1 (Fig. 3) (see
Fig. 5C). However, expression of E2F1, but not of E2F2, alters
p53 protein levels in p19ARF/ MEFs (Fig. 4 and Fig. 5C).
We next compared the ability of E2F1 and E2F2 expression
to induce a change in p53 phosphorylation. We find that ec-
topic expression of either E2F1 or E2F2 leads to an increase in
the levels of both endogenous p53 and the phospho-Ser18 form
of p53 in wild-type MEFs, although the levels of phospho-Ser18
p53 are lower in the E2F2-expressing sample (Fig. 5C). Similar
results were observed with immunofluorescence staining for
p53 and phospho-Ser18 p53 in wild-type MEFs (Fig. 3). Ex-
pression of E2F1, but not of E2F2, leads to increased levels of
the endogenous phospho-Ser18 form of p53 in p19ARF/
MEFs (Fig. 4 and Fig. 5C). In addition to phosphorylation at
Ser15 (the human equivalent to Ser18 in mouse p53), phosphor-
ylation of Ser20 (Ser23 in mouse p53) on human p53 is com-
monly observed following DNA damage (11, 29, 66). Since we
have had difficulties detecting mouse phospho-Ser23 p53 by
immunoblot analysis, cells were coinfected at a low MOI with
an adenovirus encoding human p53 which when phosphory-
lated can be detected by the anti-phospho-Ser20 antibody. Us-
ing this approach, we find that E2F1 expression results in an
increase in the phospho-Ser20 and phospho-Ser15 forms of p53
in both wild-type and p19ARF/ MEFs (Fig. 6A and B). E2F2
expression results in a slight increase in both the phospho-
Ser15 and phospho-Ser20 forms of p53 in wild-type MEFs but
not in p19ARF/ MEFs (Fig. 6A and B). This inability of
E2F2 to affect the phosphorylation of p53 in the absence of
p19ARF was also observed for the endogenous mouse p53 (Fig.
4 and Fig. 5C). The ability of E2F2 to affect p53 protein levels
was, unlike that of E2F1, solely dependent on p19ARF, since
both endogenous and exogenous p53 protein levels were un-
changed when E2F2 was expressed in p19ARF/ MEFs while
E2F1 expression leads to an increase in p53 in both wild-type
FIG. 3. E2F1 and E2F2 induce endogenous p53 accumulation and phosphorylation of the serine 18 residue of p53 in wild-type MEFs.
Immunofluorescent detection of total p53 protein (rhodamine red X) and phospho-Ser18 p53 (FITC) following E2F1 or E2F2 expression in
wild-type MEFs. DAPI (4,6-diamidino-2-phenylindole) staining is shown in blue. Merged images are also shown. Con, control virus.
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and p19ARF/ MEFs (Fig. 6C and 5C). We note that the
differential abilities of E2F1 and E2F2 to alter the ectopically
expressed p53 in p19ARF/ MEFs appears to be exaggerated
relative to the endogenous protein in these experiments. These
results suggest that E2F2 utilizes the p19ARF/Mdm2 pathway
to affect p53 levels.
p53 phosphorylation contributes to E2F1-mediated apopto-
sis. Having found a correlation between E2F1-induced phos-
phorylation of p53 and apoptosis, we determined if these co-
valent modifications are required for or contribute to E2F1-
mediated apoptosis. Studies of the DNA damage response
have suggested that it is unlikely that a single p53 modification
is responsible for activating p53-dependent apoptosis (9), so
we initially addressed this question by using a p53 mutant in
which most of the N- and C-terminal amino acid residues
known to be phosphorylated upon DNA damage have been
changed to alanines. This mutant, p53N/C, has been shown to
activate expression of p21, Mdm2, and Bax reporter constructs
as effectively as wild-type p53 and has been reported to induce
apoptosis in response to certain stimuli (2). Mdm2 has also
been shown to regulate the levels of p53N/C (2). Indeed, we
find that the p53N/C protein accumulates at levels similar to
those of wild-type p53 when expressed by recombinant adeno-
virus transduction (Fig. 7A). To measure apoptosis, p53/
MEFs were transduced with AdE2F1 or AdE2F2 and either
wild-type Adp53 or Adp53N/C (Fig. 7B). Without the addition
of p53, levels of apoptosis in E2F1- or E2F2-expressing sam-
ples were similar to those of AdCon-infected cells. Cells ex-
pressing both E2F1 and wild-type p53 underwent apoptosis. In
contrast, apoptosis was greatly reduced in cells transduced with
E2F1- and p53N/C-encoding adenoviruses, suggesting a con-
tribution by these potential phosphorylation sites to apoptosis.
As expected, E2F2 did not induce apoptosis when coexpressed
with either p53 or p53N/C.
We next examined the role of p53 kinases on apoptosis
signaling in response to E2F1 expression by using caffeine, a
potent inhibitor of several of these kinases. We find that there
is a dose-dependent decrease in apoptosis in E2F1-expressing
MEFs following treatment with increasing doses of caffeine
(Fig. 8). Treatment of cultured cells with caffeine prior to
ionizing radiation results in a delayed and attenuated accumu-
lation of p53 protein (38). This defect in p53 accumulation is
due to the inhibition of the ataxia telangiectasia mutated
(ATM) and the ATM-Rad3-related (ATR) kinases that phos-
phorylate p53 on serine 15. Inhibition of ATM and ATR will
also block subsequent signals that activate the checkpoint ki-
nases CHK1 and CHK2 and perhaps other kinases that phos-
phorylate p53 on serine 20 (5, 62). The observations that block-
ing p53 phosphorylation either by mutating potential
phosphorylation sites on p53 or treatment with the p53 kinase
inhibitor, caffeine, can significantly compromise apoptosis
demonstrates that p53 phosphorylation is a critical step in
E2F1-mediated apoptosis.
DISCUSSION
The signaling mechanism by which the Rb/E2F pathway in
general, and E2F1 specifically, communicates with p53 has
been thought to involve the p19ARF/Mdm2 pathway. Indeed,
we find that p19ARF and Mdm2 are required for the majority
FIG. 4. E2F1 specifically induces endogenous p53 accumulation and phosphorylation of the serine 18 residue of p53 in p19ARF/ MEFs.
Immunofluorescent detection of total p53 protein (Rhodamine Red-X) and phospho-Ser18 p53 (FITC) following E2F1 or E2F2 expression in
p19ARF/ MEFs. DAPI (4,6-diamidino-2-phenylindole) staining is shown in blue. Merged images are also shown. Con, control virus.
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of p53 protein accumulation observed following E2F1 expres-
sion. However, contrary to the role of the p19ARF pathway in
p53 accumulation, we find that E2F1 induces apoptosis in
MEFs lacking p19ARF (Fig. 9). It is unlikely that E2F1 induc-
tion of p73 is directly responsible for the apoptosis observed in
p19ARF/ MEFs since we show that E2F1 failed to induce
apoptosis in MEFs lacking both p19ARF and p53. These results
are in contrast to those of earlier studies which concluded that
p19ARF is important for E2F1-mediated apoptosis (16, 80).
However, during revisions to the manuscript, reports published
by Tsai et al. (70) and Tolbert et al. (68) showed that p19ARF
was not required for apoptosis in Rb-deficient mouse embryos
or following Rb inactivation by transgenic expression of a frag-
ment of the simian virus 40 large-T antigen, respectively. Like-
wise, a report published by Russell et al. showed that crossing
an E2F1 transgenic mouse into a p19ARF/ background does
not reduce apoptosis caused by expression of the E2F1 trans-
gene (61). Thus, studies that used several different models
arrived at the conclusion that the apoptosis associated with
deregulated E2F activity does not require p19ARF.
If p19ARF is not required for E2F1 to activate p53, what
role does p19ARF have in this context? Expression of p19ARF
in p53/ MEFs causes growth arrest, and overexpression of
E2F1 overcomes this arrest (8), suggesting that p19ARF may
act as a negative regulator of the Rb/E2F proliferation path-
way. We speculate that induction of the p19ARF/Mdm2/p53
pathway by the E2F family functions primarily to attenuate the
proliferation-promoting effects of E2F transcriptional activity
(Fig. 9). Indeed, human p14ARF binds E2F1 and inhibits its
transcriptional activity (20). Moreover, p19ARF physically in-
teracts with E2F1, E2F2, and E2F3 and promotes their degra-
dation in a proteasome-dependent manner (47). Another pos-
sibility is that p19ARF/Mdm2 activates p53 and modulates
proliferation by inducing the p21 cyclin-dependent kinase in-
hibitor, a known transcriptional target of p53 (18, 25, 76). In
either case, the p19ARF/Mdm2/p53 pathway would act as a
sensor and attenuator of proliferation.
It is conceivable that forcing cells into S phase by ectopic
E2F expression can induce the apoptotic response. However, it
is not likely to simply be ectopic S-phase induction following
FIG. 5. Induction of apoptosis is specific to E2F1. (A) Apoptosis analysis in wild-type (wt) MEFs infected with AdCon, AdE2F1, or AdE2F2.
At 72 hpi, cells were harvested and processed for PI staining and flow cytometry. Percentages represent cells with sub-2N DNA content.
(B) Immunoblot analysis for p19ARF in lysates of wild-type and p19ARF/ MEFs. Cells were coinfected with Adp53 and either AdCon, AdE2F1,
AdE2F1e132, or AdE2F2. Cells were harvested, and lysates were generated at 24 hpi. The actin blot is shown as a protein loading control. ns,
nonspecific band. (C) Immunoblot analysis for endogenous p53 and the phospho-Ser18 form of p53 in lysates of wild-type and p19ARF/ MEFs.
Cells were infected with AdCon, AdE2F1, AdE2F2, or AdE2F1e132. Cells were harvested, and lysates were generated at 24 hpi. The actin blot is
shown as a protein loading control.
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E2F expression that triggers apoptosis, since both E2F1 and
E2F2 can induce S phase at similar efficiencies (15), and we
find that E2F2 does not induce apoptosis in MEFs. Moreover,
there does not appear to be a specific phase of the cell cycle in
which E2F1 induces apoptosis (14, 40). Our findings that ec-
topic E2F1, but not E2F2, expression results in increased p53
phosphorylation in the absence of p19ARF and that this cova-
lent modification of p53 contributes to E2F1-mediated apo-
ptosis suggest that E2F1 may activate a cellular response sim-
ilar to DNA damage. Activation of p53 by covalent
modification, specifically phosphorylation of serine 15 (serine
18 in the mouse) and serine 20 in response to DNA damage,
has been a topic of great interest due to the location of these
residues within the Mdm2 interaction domain of p53. Muta-
tional analysis of p53 sites known to be covalently modified,
including serine 15 and serine 20, have been inconsistent re-
garding the requirements for phosphorylation at any one of
these sites for p53-dependent apoptosis in response to DNA
damage (2, 71, 75). While our study examined the phosphor-
ylation status of two N-terminal residues on p53 known to be
phosphorylated following DNA damage, we have not estab-
lished that either of these modifications are causal in p53-
mediated apoptosis, nor have we ruled out the involvement or
importance of modification(s) to other residues on p53 follow-
ing E2F1 expression. However, our finding that apoptosis is
reduced when E2F1 is coexpressed with a p53 mutant lacking
many of these phosphorylation sites demonstrates a contribu-
tion by potential p53 phosphorylation targets to E2F1-induced
apoptosis. Additionally, the observation that caffeine inhibits
E2F1-mediated apoptosis suggests that the action of one or
more p53 kinases is likely to be important for E2F1 signaling.
Signaling cascades that activate protein kinases responsible for
phosphorylating N-terminal residues on p53 upon DNA dam-
FIG. 6. Induction of p53 phosphorylation by E2F1 and E2F2. Im-
munoblot analysis for phospho-Ser15 (A) and phospho-Ser20 (B) forms
of p53 or total p53 in lysates (C) of wild-type (wt) and p19ARF/
MEFs coinfected with Adp53 and either AdCon, AdE2F1, or AdE2F2.
Cells were harvested, and lysates were generated at 24 hpi. The blot
was sequentially stripped and reprobed. Actin blots are shown as
protein loading controls.
FIG. 7. Covalent modification of p53 contributes to E2F1-medi-
ated apoptosis. (A) Immunoblot analysis of wild-type (wt) p53 and
p53N/C in lysates of p53/ MEFs infected with Adp53 or Adp53N/C
at an MOI of 10, 20, or 50. An actin blot is also shown. (B) Apoptosis
analysis in p53/ MEFs. Cells were infected with Adp53 or
Adp53N/C at an MOI of 20 and AdCon, AdE2F1, or AdE2F2 at an
MOI of 500. At 72 hpi, cells were harvested and processed for PI
staining and flow cytometry. Percentages represent cells with sub-2N
DNA content.
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age are well documented (1). Candidate kinases include ATM,
ATR, CHK1, and CHK2. ATM and ATR phosphorylate p53 at
Ser15 and activate the CHK kinases by phosphorylation (3, 7,
41, 45, 48). Active CHK kinases can then phosphorylate p53 at
Ser15 and Ser20 (66).
Recently, ATM/ATR has been shown to phosphorylate the
N terminus of E2F1 but not that of E2F2 or E2F3 (43). This
observation, together with the data presented here, leads us to
speculate that ectopic E2F1 expression or activation of endog-
enous E2F1 upon phosphorylation by ATM, leads to increases
in the activity and, perhaps, levels of one or more of the p53
kinases, which then phosphorylate p53 and promote apoptosis.
Given that the E2F1 DNA binding mutant E2F1e132 did not
induce p53 phosphorylation or apoptosis, transcriptional acti-
vation of one or more p53 kinases might provide a mechanism
for E2F1 activation of this pathway. However, overexpression
of the ATM/ATR, CHK1, or CHK2 kinases has been found to
be insufficient for their activation (45, 48). Therefore, an ad-
ditional signal(s) may be necessary to stimulate their activity.
It is conceivable that E2F1, E2F2, or E2F3 could signal
through the p19ARF/Mdm2 pathway to increase p53 protein
levels and that the increased pools of p53 would provide more
substrate for the p53 kinases activated by E2F1 (Fig. 9). Thus,
the p19ARF/Mdm2 pathway may act both as an attenuator of
proliferation by targeting E2F family members for degradation
and as an amplifier of a DNA damage signal by increasing
pools of p53 available for phosphorylation. The decision to
undergo growth arrest or apoptosis would then depend on the
cellular context or extent of DNA damage.
Our data implicates p53 phosphorylation as a key step in
E2F1-mediated p53-dependent apoptosis. These observations
raise the possibility that E2F1 signaling and DNA damage
response pathways may converge and involve the same or re-
lated kinases to activate p53. Alternatively, E2F1 may contrib-
ute to or be a component of the DNA damage pathway. Given
these possibilities, it is possible that a role of E2F1 may be to
amplify DNA damage signals, resulting in p53-mediated apo-
ptosis. Future studies are needed to test this hypothesis and to
define the kinase(s) involved in p53 phosphorylation and the
mechanisms by which E2F1 activates them.
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